Synthesis and antibacterial, antimycobacterial and docking studies of novel N-piperazinyl fluoroquinolones

Medicinal Chemistry Research

Volumn 22, Issue 2, 2013, Pages 818-831

  Agrawal, Kapil M ^a   Talele, Gokul S ^b  

^a R C PATEL INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH   (India)

^b Department of Pharmaceutical Chemistry   (India)

Author keywords

Antibacterial; Antimycobacterial; Cytotoxicity; Docking study; Fluoroquinolone (FQ)

Indexed keywords

1 CYCLOPROPYL 6 FLUORO 1,4 DIHYDRO 7 [4 [5 (2 OXO 2 P BROMOPHENYLETHYLTHIO) 1,3,4 THIADIAZOL 2 YL]PIPERAZIN 1 YL] 4 OXOQUINOLINE 3 CARBOXYLIC ACID; 1 CYCLOPROPYL 6 FLUORO 1,4 DIHYDRO 7 [4 [5 (2 OXO 2 P FLUOROPHENYLETHYLTHIO) 1,3,4 THIADIAZOL 2 YL]PIPERAZIN 1 YL] 4 OXOQUINOLINE 3 CARBOXYLIC ACID; 1 CYCLOPROPYL 6 FLUORO 1,4 DIHYDRO 7 [4 [5 (2 OXO 2 P METHOXYPHENYLETHYLTHIO) 1,3,4 THIADIAZOL 2 YL]PIPERAZIN 1 YL] 4 OXOQUINOLINE 3 CARBOXYLIC ACID; 1 CYCLOPROPYL 6 FLUORO 1,4 DIHYDRO 7 [4 [5 (2 OXO 2 P PHENYLETHYLTHIO) 1,3,4 THIADIAZOL 2 YL]PIPERAZIN 1 YL] 4 OXOQUINOLINE 3 CARBOXYLIC ACID; 1 CYCLOPROPYL 6 FLUORO 1,4 DIHYDRO 7 [4 [5 (2 OXO 2 P TOLYLETHYLTHIO) P TOLYLETHYLTHIO) 1,3,4 THIADIAZOL 2 YL]PIPERAZIN 1 YL] 4 OXOQUINOLINE 3 CARBOXYLIC ACID; 1 CYCLOPROPYL 6 FLUORO 1,4 DIHYDRO 7 [4 [5 (2 OXO 2 PCHLOROPHENYLETHYLTHIO) 1,3,4 THIADIAZOL 2 YL]PIPERAZIN 1 YL] 4 OXOQUINOLINE 3 CARBOXYLIC ACID; 1 CYCLOPROPYL ETHYL 6 FLUORO 1,4 DIHYDRO 7 [4 [5 (2 OXO 2 P(SUBSTITUTED) PHENYLETHYLTHIO) 1,3,4 THIADIAZOL 2 YL]PIPERAZIN 1 YL] 4 OXOQUINOLINE 3 CARBOXYLIC ACID; 1 ETHYL 6 FLUORO 1,4 DIHYDRO 7 [4 [5 (2 OXO 2 P BROMOPHENYLETHYLTHIO) 1,3,4 THIADIAZOL 2 YL]PIPERAZIN 1 YL] 4 OXOQUINOLINE 3 CARBOXYLIC ACID; 1 ETHYL 6 FLUORO 1,4 DIHYDRO 7 [4 [5 (2 OXO 2 P CHLOROPHENYLETHYLTHIO) 1,3,4 THIADIAZOL 2 YL]PIPERAZIN 1 YL] 4 OXOQUINOLINE 3 CARBOXYLIC ACID; 1 ETHYL 6 FLUORO 1,4 DIHYDRO 7 [4 [5 (2 OXO 2 P METHOXYPHENYLETHYLTHIO) 1,3,4 THIADIAZOL 2 YL]PIPERAZIN 1 YL] 4 OXOQUINOLINE 3 CARBOXYLIC ACID; 1 ETHYL 6 FLUORO 1,4 DIHYDRO 7 [4 [5 (2 OXO 2 P TOLYLETHYLTHIO) 1,3,4 THIADIAZOL 2 YL]PIPERAZIN 1 YL] 4 OXOQUINOLINE 3 CARBOXYLIC ACID; 1 ETHYL 6 FLUORO 1,4 DIHYDRO 7 [4 [5 (2 OXO 2 PFLUOROPHENYLETHYLTHIO) 1,3,4 THIADIAZOL 2 YL]PIPERAZIN 1 YL] 4 OXOQUINOLINE 3 CARBOXYLIC ACID; 1 ETHYL 6 FLUORO 1,4 DIHYDRO 7 [4 [5 (2 OXO 2 PHENYLETHYLTHIO) 1,3,4 THIADIAZOL 2 YL]PIPERAZIN 1 YL] 4 OXOQUINOLINE 3 CARBOXYLIC ACID; 2 AMINO 5 BENZOYLMETHYLENETHIO 1,3,4 THIADIAZOLE; 2 AMINO 5 MERCAPTO 1,3,4 THIADIAZOLE; 2 CHLORO 5 BENZOYLMETHYLENETHIO 1,3,4 THIADIAZOLE; ANTIMYCOBACTERIAL AGENT; CHLOROBENZOYLMETHYLENETHIO 1,3,4 THIADIAZOLE; CIPROFLOXACIN; ISONIAZID; NORFLOXACIN; QUINOLONE DERIVATIVE; RIFAMPICIN; TUBERCULOSTATIC AGENT; UNCLASSIFIED DRUG;

ANTIBACTERIAL ACTIVITY; ARTICLE; CONTROLLED STUDY; CORYNEBACTERIUM; CYTOTOXICITY; DRUG BINDING; DRUG POTENCY; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; ESCHERICHIA COLI; IN VITRO STUDY; MICROCYSTIS AERUGINOSA; MOLECULAR DOCKING; STAPHYLOCOCCUS AUREUS; STRUCTURE ACTIVITY RELATION;

EID: 84873986494     PISSN: 10542523     EISSN: 15548120     Source Type: Journal    
DOI: 10.1007/s00044-012-0074-2     Document Type: Article

References (37)

1. Becerra MC, Freeman J, Bayona J, Shin SS, Kim JY, Furin JJ (2000) Using treatment failure under effective directly observed short-course chemotherapy programs to identify patients with multidrug-resistant tuberculosis. Int J Tuberc Lung Dis 4:108-114
2. Cambau E, Sougakoff W, Besson M, Truffot-Pernot C, Grosset J, Jarlier V (1994) Selection of a gyrA mutant of Mycobacterium tuberculosis resistant to fluoroquinolones during treatment with ofloxacin. J Infect Dis 170:479-483
3. Chu DTW, Fernandes PB, Claiborne AK, Pihuleac E, Nordeen CW, Maleczka RE, Pernet AG (1985) Synthesis and structure-activity relationships of novel arylfluoroquinolone antibacterial agents. J Med Chem 28:1558-1564
4. Coleman GH and Honeywell GE (1943) Organic syntheses, Coll. vol. 2. Wiley, New York, pp 443-445
5. Conde MB, Efron A, Loredo C, DeSouza GRM, Graça NP, Cezar MC (2009) Moxifloxacin versus ethambutol in the initial treatment of tuberculosis: a double-blind, randomised, controlled phase II trial. Lancet 373:1183-1189
6. Cowper RM and Davidson LH (1943) Phenacyi bromide. In: Blatt AH (ed) Organic syntheses, Coll. vol. 2. Wiley, New York, pp 480-481
7. Domagala JM, Heifetz CL, Hutt MP, Mich TF, Nichols JB, Solomon M, Worth DF (1988) Quinolone antibacterial agents: synthesis and structure-activity relationships of 8-substituted quinoline-3-carboxylic acids and 1,8-naphthyridine-3-carboxylic acids. J Med Chem 31:983-991
8. Dorman SE, Johnson JL, Goldberg S, Muzanye G, Padayatchi N, Bozeman L (2009) Substitution of moxifloxacin for isoniazid during intensive phase treatment of pulmonary tuberculosis. Am J Respir Crit Care Med 180:273-280
9. Dutt AK, Stead WW (1999) Tuberculosis and nontuberculosis mycobacterial infections. WB Saunders, New York, p 3
10. Espinal MA, Kim SJ, Suarez PG, Kam KM, Khomenko AG, Migliori GB (2000) Standard short-course chemotherapy for drug-resistant tuberculosis: treatment outcomes in 6 countries. JAMA 283:2537-2545
11. Foroumadi A, Daneshtalab M, Shafiee A (1999) Synthesis and in vitro antifungal activity of 2-aryl-5-phenylsulfonyl-1,3,4-thiadiazole derivatives. Arzneim-Forsch/Drug Res 49: 1035-1038
12. Foroumadi A, Emami S, Hassanzadeh A, Razaee M, Shokhanvar K, Moshafi MH, Shafee A (2005) Synthesis and antibacterial activity of N-(5-benzylthio-1,3,4- thiadiazol-2-yl) piperazinyl quinolone derivatives. Bioorg Med Chem Lett 15:4488-4492
13. Freund M, Imgart H (1895) Dithiourazol and some of its derivative. Ber Dtsch Chem Ges 28:946-957
14. Gadad AK, Talath S (2006) Synthesis, antibacterial and antitubercular activities of some 7-[4-(5-amino-[1,3,4] thiadiazole-2-sulfonyl)-piperazin-1-yl] fluoroquinolone derivatives. Eur J Med Chem 41:918-924
15. Ghosh P and Bagchi MC (2010) Anti-tubercular drug designing by structure based screening of combinatorial libraries. J Mol Model 17(7): 1607-1620. doi: 10.1007/s00894-010-0861-y
16. Glide version 4.5 (2007) Schrödinger LLC, New York
17. Goto S, Sakamoto H, Ogawa M, Tsuji A, Kuwahara S (1982) Bactericidal activity of cefazolin, cefoxitin and cefmetazole against Escherichia coli and Klebsiella pneumoniae. Chemotherapy 28:18-25
18. Grosset JH (1992) Treatment of tuberculosis in HIV infection. Tuberc Lung Dis 1992(73):378-383
19. LigPrep-v2.1 Molecular modeling interface (2007) Schrödinger LLC, New York
20. Maestro-v8.0 molecular modeling interface (2007) Schrödinger LLC, New York
21. Manzo RH, Allemandi DA, Perez JD (1992) Argentine patent application 322011. US Patent 5,395,936, 1995
22. Metropolis N, Rosenbluth AW, Rosenbluth MN, Teller AH (1953) Equation of state calculations by fast computing machines. E J Chem Phys 21:1087-1092
23. Migliori GB, Espinal M, Danilova ID, Punga VV, Grzemska M, Raviglione MC (2002) Frequency of recurrence among MDR-tB cases 'successfully' treated with standardised short-course chemotherapy. Int J Tuberc Lung Dis 6:858-864
24. Migliori GB, Lange C, Girardi E, Centis R, Besozzi G, Kliiman K (2008a) Fluoroquinolones: are they essential to treat multidrug-resistant tuberculosis. Eur Respir J 31:904-905
25. Migliori GB, Lange C, Girardi E, Centis R, Besozzi G, Kliiman K (2008b) Extensively drug-resistant tuberculosis is worse than multidrug-resistant TB different methodology and settings same results. Clin Infect Dis 46:958-959
26. Morrison RT, Boyd RN (2004) Organic chemistry. Pearson Education, New Delhi, pp 564-567
27. Naidir FB and Khim FZh (1982) Dictionary of organic compounds. 5th ed. Chapman and Hall, New York, p 847
28. Protein Preparation Wizard (2007) Schrödinger LLC, New York
29. Rattan A, Kalia A, Ahmad N (1998) Multidrug-resistant Mycobacterium tuberculosis: molecular perspectives. Emerg Infect Dis 4:195-209
30. Rustomjee R, Lienhardt C, Kanyok T, Davies GR, Levin J, Mthiyane T (2008) A Phase II study of the sterilising activities of ofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis. Int J Tuberc Lung Dis 12:128-138
31. Shen LL, Mitscher LA, Sharma PN, O'Donnell TJ, Chu DWT, Cooper CS, Rosen T, Pernet AG (1989) Mechanism of inhibition of DNA gyrase by quinolone antibacterials: a cooperative drug-DNA binding model. Biochemistry 28:3886-3894
32. Sriram D, Yogeeswari P, Reddy SP (2006) Synthesis of pyrazinamide mannich bases and its antitubercular properties. Bioorg Med Chem Lett 16:2113-2116
33. Suling WJ, Seitz LEV, Pathak L, Westbrook EW, Barrow S, Ginkel ZV, Reynolds RC, Robert PJ, Barrow WW (2000) Antimycobacterial Activities of 2,4-Diamino-5-deazapteridine derivatives and effects on mycobacterial dihydrofolate reductase. Antimicrob Agents Chemother 44:2784-2793
34. Tsukamura M, Nakamura E, Yoshii S, Amano H (1985) Therapeutic effect of a new antibacterial substance ofloxacin (DL8280) on pulmonary tuberculosis. Am Rev Respir Dis 131:352-356
35. WHO/HTM/TB/2008.402 (2008) Guidelines for the programmatic management of drug-resistant tuberculosis. Emergency update, Geneva
36. Yajko DM, Madej JJ, Lacaster MV, Sanders CA, Cawthon VL, Gee BA, Hardley BWK (1995) Colorimetric method for determining MICs of antimicrobial agents for Mycobacterium tuberculosis. J Clin Microb 33:2324-2327
37. Yew WW, Chan CK, Chau CH, Tam CM, Leung CC, Wong PC (2000) Outcomes of patients with multidrug-resistant pulmonary tuberculosis treated with ofloxacin/levofloxacin-containing regimens. Chest 117:744-751